Form 4: Prothena Corp Public Ltd Co: Chief Scientific Officer Acquires Stock Options
SEC Form 4 Filing
Wagner M. Zago, Chief Scientific Officer of Prothena Corp Public Ltd Co, reports the acquisition of stock options for 107,500 ordinary shares.
Summary
- Wagner M. Zago, the Chief Scientific Officer of Prothena Corp Public Ltd Co, filed a Form 4 with the SEC.
- The filing reports the acquisition of stock options to purchase 107,500 ordinary shares.
- The options were granted on March 5, 2025, with an exercise price of $14.95.
- The options vest over a four-year period, starting March 5, 2026, with 25% vesting on that date and the remainder vesting monthly thereafter, contingent upon continued employment.
- The options expire on March 5, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future performance.
Positives
- The grant of stock options to a key executive like the Chief Scientific Officer can be seen as a positive incentive for continued performance and alignment with shareholder interests.
Future Outlook
The document does not contain any specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize key employees and align their interests with the long-term success of the company. This filing reflects standard compensation practices.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their executives.
- The vesting schedule and exercise price are generally in line with industry norms for similar roles and company size.
Stakeholder Impact
- The stock option grant could potentially incentivize the Chief Scientific Officer to drive innovation and create value for shareholders.
- Employees may view this as a positive sign of investment in key personnel.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of the stock option grant and earliest transaction. |
| 03/05/2026 | First vesting date for 25% of the stock options. |
| 03/05/2035 | Expiration date of the stock options. |
| 03/07/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.